AAAAAA

   
Results: 1-11 |
Results: 11
Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families
Authors: Lahti-Domenici, J Rapakko, K Paakkonen, K Allinen, M Nevanlinna, H Kujala, M Huusko, P Winqvist, R
Citation: J. Lahti-domenici et al., Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families, CANC GENET, 129(2), 2001, pp. 120-123
Mutation analysis of the CHK2 gene in families with hereditary breast cancer
Authors: Allinen, M Huusko, P Mantyniemi, S Launonen, V Winqvist, R
Citation: M. Allinen et al., Mutation analysis of the CHK2 gene in families with hereditary breast cancer, BR J CANC, 85(2), 2001, pp. 209-212
Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites
Authors: Rapakko, K Allinen, M Syrjakoski, K Vahteristo, P Huusko, P Vahakangas, K Eerola, H Kainu, T Kallioniemi, OP Nevanlinna, H Winqvist, R
Citation: K. Rapakko et al., Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites, BR J CANC, 84(1), 2001, pp. 116-119
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
Authors: Sarantaus, L Huusko, P Eerola, H Launonen, V Vehmanen, P Rapakko, K Gillanders, E Syrjakoski, K Kainu, T Vahteristo, P Krahe, R Paakkonen, K Hartikainen, J Blomqvist, C Lopponen, T Holli, K Ryynanen, M Butzow, R Borg, A Arver, BW Holmberg, E Mannermaa, A Kere, J Kallioniemi, OP Winqvist, R Nevanlinna, H
Citation: L. Sarantaus et al., Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland, EUR J HUM G, 8(10), 2000, pp. 757-763
Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables
Authors: Launonen, V Mannermaa, A Stenback, F Kosma, VM Puistola, U Huusko, P Anttila, M Bloigu, R Saarikoski, S Kauppila, A Winqvist, R
Citation: V. Launonen et al., Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables, CANC GENET, 122(1), 2000, pp. 49-54
Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study
Authors: Laake, K Launonen, V Niederacher, D Gudlaugsdottir, S Seitz, S Rio, P Champeme, MH Bieche, I Birnbaum, D White, G Sztan, M Sever, N Plummer, S Osorio, A Broeks, A Huusko, P Spurr, N Borg, A Cleton-Jansen, AM van't Veer, L Benitez, J Casey, G Peterlin, B Olah, E Varley, J Bignon, YJ Scherneck, S Sigurdardottir, V Lidereau, R Eyfjord, J Beckmann, MW Winqvist, R Skovlund, E Borresen-Dale, AL
Citation: K. Laake et al., Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study, GENE CHROM, 25(3), 1999, pp. 212-221
Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414de14 found in male breast cancer
Authors: Balci, A Huusko, P Paakkonen, K Launonen, V Uner, A Ekmekci, A Winqvist, R
Citation: A. Balci et al., Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414de14 found in male breast cancer, EUR J CANC, 35(5), 1999, pp. 707-710
Germ-line TP53 mutations in Finnish cancer families exhibiting features ofthe Li-Fraumeni syndrome and negative for BRCA1 and BRCA2
Authors: Huusko, P Castren, K Launonen, V Soini, Y Paakkonen, K Leisti, J Vahakangas, K Winqvist, R
Citation: P. Huusko et al., Germ-line TP53 mutations in Finnish cancer families exhibiting features ofthe Li-Fraumeni syndrome and negative for BRCA1 and BRCA2, CANC GENET, 112(1), 1999, pp. 9-14
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables
Authors: Launonen, V Laake, K Huusko, P Niederacher, D Beckmann, MW Barkardottir, RB Geirsdottir, EK Gudmundsson, J Rio, P Bignon, YJ Seitz, S Scherneck, S Bieche, I Champeme, MH Birnbaum, D White, G Varley, J Sztan, M Olah, E Osorio, A Benitez, J Spurr, N Velikonja, N Peterlin, B Borg, A Cleton-Jansen, AM Devilee, P Bloigu, R Lidereau, R Borresen-Dale, AL Winqvist, R
Citation: V. Launonen et al., European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables, BR J CANC, 80(5-6), 1999, pp. 879-882
Genetics and epidemiology of hereditary breast cancer
Authors: Devilee, P Barkardottir, RB Bevilacqua, G Bignon, YJ Bishop, T Borg, A Borresen-Dale, AL Chang-Claude, J Easton, D Eyfjord, J Feunteun, J Goldgar, D Haites, N Holm, N Kruse, T Larsson, C Lenoir, G Lidereau, R Nevanlinna, H Ponder, B Scherneck, S Schmitt, F Sobol, H Solomon, E Spurr, N Steel, M Stratton, M Varley, J Vasen, H Vassilaros, S Wagner, T Willems, P Winqvist, R
Citation: P. Devilee et al., Genetics and epidemiology of hereditary breast cancer, BIOM HLTH R, 24, 1998, pp. 339-346
Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions
Authors: Launonen, V Stenback, F Puistola, U Bloigu, R Huusko, P Kytola, S Kauppila, A Winqvist, R
Citation: V. Launonen et al., Chromosome 11q22.3-q25 LOH in ovarian cancer: Association with a more aggressive disease course and involved subregions, GYNECOL ONC, 71(2), 1998, pp. 299-304
Risultati: 1-11 |